Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.
Marjolein Y A M KroonenJeroen V KoomenSergei I PetrykivGozewijn D LavermanHiddo J Lambers HeerspinkJasper StevensPublished in: Diabetes, obesity & metabolism (2020)
An individual's exposure to dapagliflozin is consistent upon re-exposure and correlates with pharmacodynamic response in renal risk markers.
Keyphrases